Juno Therapeutics (NASDAQ:JUNO)‘s stock had its “market perform” rating reissued by analysts at Wells Fargo & Co in a research note issued on Wednesday, The Fly reports. They currently have a $63.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $54.00. Wells Fargo & Co’s target price points to a potential upside of 38.16% from the company’s previous close.

A number of other brokerages have also commented on JUNO. Raymond James Financial raised their price target on Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 price objective on shares of Juno Therapeutics in a report on Friday, October 6th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Juno Therapeutics in a report on Thursday, January 11th. Citigroup reiterated a “buy” rating and issued a $59.00 price objective on shares of Juno Therapeutics in a report on Tuesday, October 31st. Finally, Maxim Group reiterated a “buy” rating and issued a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $47.26.

Shares of Juno Therapeutics (NASDAQ JUNO) opened at $45.60 on Wednesday. Juno Therapeutics has a 52 week low of $18.90 and a 52 week high of $63.45. The company has a market capitalization of $5,210.00, a price-to-earnings ratio of -13.45 and a beta of 2.32. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The company had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the firm posted ($0.57) earnings per share. The firm’s revenue was up 115.4% on a year-over-year basis. analysts expect that Juno Therapeutics will post -4.02 EPS for the current fiscal year.

In other news, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the completion of the transaction, the chief financial officer now directly owns 772,082 shares in the company, valued at $34,558,390.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares of the company’s stock, valued at $4,395,890.10. The disclosure for this sale can be found here. Insiders have sold 65,956 shares of company stock valued at $3,064,378 over the last 90 days. Corporate insiders own 15.08% of the company’s stock.

Several large investors have recently modified their holdings of JUNO. Capital International Investors bought a new position in shares of Juno Therapeutics during the third quarter valued at $256,339,000. Redmile Group LLC bought a new position in shares of Juno Therapeutics during the second quarter valued at $66,344,000. Jennison Associates LLC increased its holdings in shares of Juno Therapeutics by 162.0% during the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock valued at $89,213,000 after acquiring an additional 1,229,622 shares in the last quarter. Orbimed Advisors LLC increased its holdings in shares of Juno Therapeutics by 123.1% during the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock valued at $91,587,000 after acquiring an additional 1,126,400 shares in the last quarter. Finally, Capital Guardian Trust Co. bought a new position in shares of Juno Therapeutics during the third quarter valued at $37,400,000. Hedge funds and other institutional investors own 69.94% of the company’s stock.

WARNING: “Juno Therapeutics’ (JUNO) Market Perform Rating Reiterated at Wells Fargo & Co” was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/juno-therapeutics-juno-market-perform-rating-reiterated-at-wells-fargo-co/1810614.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

The Fly

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.